iBio, Inc.

IBIO·NasdaqCM
Compare
0.9032+0.0322 (+3.70%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours0.9199+0.0167 (+1.85%)Oct 12, 5:42 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.8710
Open0.8900
Day range0.88490.9500
52-week range0.79003.8200
Off day high−4.93%
Off 52-week high−76.36%
Volume449.31K
Avg. volume (3M)739.61K
Market cap58.08M
EPS (TTM)-0.3200
Forward P/E-1.47
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding64.31M
Short interest—
Earnings dateSep 18, 2025 (est.)
Analyst target—
Profit margin—

Against its peers

Compare in full ›
IBIO OABI INMB BMEA IMUX VRXA
Market cap 58.08M 693.51M 49.40M 98.33M 108.47M 161.20M
P/E (TTM) — — — — — —
Forward P/E -1.5 -16.3 -4.1 -1.4 -3.3 —
Price/book 0.6 2.7 2.4 8.1 0.9 -0.9
Dividend yield — — — — — —
1-year change +7.41% +195.68% +3.28% −18.56% −8.49% −87.97%
Today +3.70% −0.42% −5.82% −4.23% −2.93% −9.52%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All IBIO news ›
markets.businessinsider.com·Positive

iBio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks ... iBio initiated with a Buy at H.C. Wainwright H.C. Wainwright initiated coverage of iBio…

The Globe and Mail·Positive

iBio Announces Proposed Public Offering

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the ... iBio Announces Proposed Public…

The Globe and Mail·Negative

iBio Highlights Breakthrough Antibody Strategy for Obesity

An announcement from Ibio ( (IBIO) ) is now available. The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page. Spark’s…

markets.businessinsider.com·Positive

iBio appoints Molly Carr as chief medical officer

iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline... iBio appoints Molly Carr as chief medical officer iBio (IBIO) announced the appointment of…

bioworld.com·Positive

Ibio’s IBIO-610 reshapes weight loss composition

Human genetic and RNA-silencing studies suggest that reduced Activin E-ALK7 signaling is associated with favorable metabolic outcomes, supporting investigation of the pathway as a potential target for obesity treatment. Researchers from…

From articles in the 4Search news index.

In the news

11mentions in 30 days
11with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.